title: Linear immunoglobulin A bullous dermatosis induced by gemcitabine.
abstract: OBJECTIVE
  To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.
  
  
  METHODS
  A 59-year-old man was diagnosed with squamous-cell carcinoma of the lung in T4N2M0 stage and treated with cisplatin, vinorelbine, and gemcitabine. Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs. Histopathologic examination and direct immunofluorescence test were consistent with IgA bullous dermatosis. Cutaneous lesions resolved two weeks after the drug was withdrawn and topical steroid treatment was instituted.
  
  
  CONCLUSIONS
  Drug-induced LABD is a variant of classic or idiopathic LABD. Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD. According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.
  
  
  CONCLUSIONS
  We report the first case of gemcitabine-induced LABD. Clinicians should monitor patients receiving this drug for signs of LABD.
authors.affiliation: Department of Dermatology, Hospital Juan Canalejo, La Coruña, Spain. der@canalejo.org
authors.forename: J
authors.initials: J
authors.lastname: del Pozo
authors.forename: W
authors.initials: W
authors.lastname: Martínez
authors.forename: M T
authors.initials: MT
authors.lastname: Yebra-Pimentel
authors.forename: M
authors.initials: M
authors.lastname: Almagro
authors.forename: C
authors.initials: C
authors.lastname: Peña-Penabad
authors.forename: E
authors.initials: E
authors.lastname: Fonseca
mesh_terms: D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D005938:Glucocorticoids; D006801:Humans; D007070:Immunoglobulin A / Q000378:metabolism*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000093542:Gemcitabine
chemical_list: D000893:Anti-Inflammatory Agents; D000964:Antimetabolites, Antineoplastic; D005938:Glucocorticoids; D007070:Immunoglobulin A; D003841:Deoxycytidine; D008775:Methylprednisolone; D000093542:Gemcitabine